Ladenburg Thalmann Financial Services’s IGC Pharma IGC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
$0 Hold
500
﹤0.01% 5405
2019
Q3
$0 Sell
500
-1,300
-72% -$1.56K ﹤0.01% 5354
2019
Q2
$3K Sell
1,800
-2,500
-58% -$3.53K ﹤0.01% 4872
2019
Q1
$9K Buy
+4,300
New +$9.77K ﹤0.01% 4421
2018
Q4
Sell
-8,375
Closed -$63K 5258
2018
Q3
$63K Buy
8,375
+6,875
+458% +$7.14K ﹤0.01% 3159
2018
Q2
$1K Hold
1,500
﹤0.01% 4982
2018
Q1
$1K Hold
1,500
﹤0.01% 4982
2017
Q4
$2K Hold
1,500
﹤0.01% 4782
2017
Q3
$1K Hold
1,500
﹤0.01% 4792
2017
Q2
$1K Hold
1,500
﹤0.01% 4734
2017
Q1
$1K Hold
1,500
﹤0.01% 4709
2016
Q4
$0 Hold
1,500
﹤0.01% 4884
2016
Q3
$1K Hold
1,500
﹤0.01% 4616
2016
Q2
$1K Hold
1,500
﹤0.01% 4566
2016
Q1
$1K Hold
1,500
﹤0.01% 4519
2015
Q4
$0 Hold
1,500
﹤0.01% 4724
2015
Q3
$0 Hold
1,500
﹤0.01% 4662
2015
Q2
$1K Hold
1,500
﹤0.01% 4494
2015
Q1
$1K Hold
1,500
﹤0.01% 4422
2014
Q4
$1K Buy
+1,500
New +$1.09K ﹤0.01% 4205

Other funds holding IGC

Ladenburg Thalmann Financial Services's IGC Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services held its IGC Pharma (IGC) position steady in Q4 2019 at 500 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5405.

Ladenburg Thalmann Financial Services first reported a position in IGC in Q4 2014 and has held it in 20 quarters since. The position peaked at $63K in Q3 2018. 26 funds tracked by Wall St. Rank hold IGC as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 500 shares of IGC Pharma worth $0 as of Q4 2019.
  • Ladenburg Thalmann Financial Services left its IGC Pharma share count unchanged in Q4 2019.
  • IGC Pharma made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #5405 holding.
  • Ladenburg Thalmann Financial Services first reported a position in IGC Pharma in Q4 2014 and has held it in 20 quarters since.
  • Ladenburg Thalmann Financial Services's IGC Pharma position peaked at $63K in Q3 2018.
  • 26 funds tracked by Wall St. Rank held IGC Pharma as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.